NASDAQ:IMGN - ImmunoGen Stock Price, Price Target & More

Get Started

$10.43 -0.15 (-1.42 %)

(As of 05/25/2018 04:00 PM ET)

Previous Close$10.43

Today's Range$10.17 - $10.54

52-Week Range$4.26 - $13.41

Volume1.46 million shs

Average Volume2.12 million shs

Market Capitalization$1.41 billion

P/E Ratio-13.91

Dividend YieldN/A

Beta2.17

About ImmunoGen (NASDAQ:IMGN)

ImmunoGen, Inc., a clinical-stage biotechnology company, focuses on developing antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm, as well as coltuximab ravtansine, a CD19-targeting ADC, which is in Phase II trial for DLBCL. ImmunoGen, Inc. has collaborations with Roche; Bayer HealthCare AG; Sanofi; Biotest AG; Novartis Institutes for BioMedical Research, Inc.; Eli Lilly and Company; Amgen; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Jazz Pharmaceuticals plc; and Debiopharm International SA. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Receive IMGN News and Ratings via Email

Sign-up to receive the latest news and ratings for IMGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:IMGN

CUSIP45253H10

Webwww.immunogen.com

Phone781-895-0600

Debt

Debt-to-Equity Ratio-0.06

Current Ratio3.74

Quick Ratio3.73

Price-To-Earnings

Trailing P/E Ratio-13.91

Forward P/E Ratio-9.23

P/E GrowthN/A

Sales & Book Value

Annual Sales$115.45 million

Price / Sales12.02

Cash FlowN/A

Price / CashN/A

Book Value($0.27) per share

Price / Book-38.63

Profitability

EPS (Most Recent Fiscal Year)($0.75)

Net Income$-96,010,000.00

Net Margins-109.85%

Return on EquityN/A

Return on Assets-39.05%

Miscellaneous

Employees293

Outstanding Shares133,040,000

ImmunoGen (NASDAQ:IMGN) Frequently Asked Questions

What is ImmunoGen's stock symbol?

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

How were ImmunoGen's earnings last quarter?

ImmunoGen (NASDAQ:IMGN) issued its earnings results on Friday, May, 4th. The biotechnology company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.27) by $0.03. The biotechnology company earned $19.80 million during the quarter, compared to analysts' expectations of $15.04 million. The firm's revenue was down 30.5% on a year-over-year basis. During the same quarter last year, the firm earned ($0.20) EPS. View ImmunoGen's Earnings History.

What price target have analysts set for IMGN?

8 brokers have issued twelve-month price objectives for ImmunoGen's shares. Their forecasts range from $5.00 to $20.00. On average, they expect ImmunoGen's stock price to reach $13.1667 in the next year. View Analyst Ratings for ImmunoGen.

What are Wall Street analysts saying about ImmunoGen stock?

Here are some recent quotes from research analysts about ImmunoGen stock:

1. According to Zacks Investment Research, "ImmunoGen is heavily dependent on its lead ovarian cancer candidate, mirvetuximab soravtansine. Hence, any kind of development or a regulatory setback could hamper the stock. The ovarian cancer space being competitive is also a matter of concern for the company. On the flip side, the company has made a significant progress with mirvetuximab soravtansine. Successful development and subsequent approval of the candidate will be a huge boost to the company as the ovarian cancer market has immense potential. The company has collaborations with big healthcare companies which not only validate its technology but also provides it with funds in the form of milestone and royalty payments. However, the company’s high dependence on its partnerships for revenue is concerning. The company’s shares have outperformed the broader industry in a year's time. Estimates have been stable lately ahead of the company’s Q1 earnings release." (4/16/2018)
2. Cantor Fitzgerald analysts commented, "FORWARD Progress. The nearest term commercial opportunity for IMGN is the FORWARD I trial, which is exploring mirvetuximab soravtansine (mirva") as a single agent in 3rd line ovarian cancer in women who express high levels of the FRa receptor. This trial could read out in 2019 pending completion of enrollment in 2018." (11/3/2017)
3. Cowen Inc analysts commented, "IMGN announced a collaboration agreement with Jazz for the development and." (8/29/2017)

Are investors shorting ImmunoGen?

ImmunoGen saw a increase in short interest during the month of April. As of April 13th, there was short interest totalling 13,024,063 shares, an increase of 17.9% from the March 30th total of 11,049,179 shares. Based on an average daily volume of 2,202,365 shares, the days-to-cover ratio is presently 5.9 days. Approximately 10.0% of the company's stock are short sold.

Who are some of ImmunoGen's key competitors?

Some companies that are related to ImmunoGen include Catalent (CTLT), GALAPAGOS NV/S (GLPG), Agios Pharmaceuticals (AGIO), Loxo Oncology (LOXO), Dr. Reddy's Laboratories (RDY), Taro Pharmaceutical Industries (TARO), United Therapeutics (UTHR), GW Pharmaceuticals (GWPH), FibroGen (FGEN), Hutchison China MediTech (HCM), Ligand Pharmaceuticals (LGND), Blueprint Medicines (BPMC), Array Biopharma (ARRY), Ultragenyx Pharmaceutical (RARE) and Amicus Therapeutics (FOLD).

Who are ImmunoGen's key executives?

ImmunoGen's management team includes the folowing people:

Mr. Mark J. Enyedy, Pres, CEO & Director (Age 54)
Mr. David B. Johnston, Exec. VP, CFO & Principal Accounting Officer (Age 63)
Dr. Richard J. Gregory, Exec. VP & Chief Scientific Officer (Age 60)
Dr. Anna Berkenblit, VP & Chief Medical Officer (Age 48)
Ms. Carol Hausner, Exec. Director of Investor Relations & Corp. Communications

Has ImmunoGen been receiving favorable news coverage?

News stories about IMGN stock have been trending somewhat positive this week, according to Accern Sentiment. Accern ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ImmunoGen earned a news impact score of 0.11 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 47.50 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Who are ImmunoGen's major shareholders?

ImmunoGen's stock is owned by many different of institutional and retail investors. Top institutional investors include Redmile Group LLC (7.29%), BlackRock Inc. (6.28%), Franklin Resources Inc. (2.01%), Wells Fargo & Company MN (1.35%), PointState Capital LP (1.26%) and Pinnacle Associates Ltd. (0.95%). Company insiders that own ImmunoGen stock include Craig Barrows, Daniel M Junius, David Brannon Johnston, Mark Alan Goldberg, Mark J Enyedy and Richard J Gregory. View Institutional Ownership Trends for ImmunoGen.

Which major investors are selling ImmunoGen stock?

IMGN stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, JPMorgan Chase & Co., Franklin Resources Inc., BlackRock Inc., Royal Bank of Canada, Guggenheim Capital LLC, Pinnacle Associates Ltd. and Stifel Financial Corp. Company insiders that have sold ImmunoGen company stock in the last year include Craig Barrows, Daniel M Junius, David Brannon Johnston, Mark J Enyedy and Richard J Gregory. View Insider Buying and Selling for ImmunoGen.

Which major investors are buying ImmunoGen stock?

IMGN stock was acquired by a variety of institutional investors in the last quarter, including PointState Capital LP, UBS Group AG, Wells Fargo & Company MN, Trexquant Investment LP, Summit Trail Advisors LLC, Allianz Asset Management GmbH, Allianz Asset Management GmbH and A.R.T. Advisors LLC. Company insiders that have bought ImmunoGen stock in the last two years include Craig Barrows, Mark Alan Goldberg, Mark J Enyedy and Richard J Gregory. View Insider Buying and Selling for ImmunoGen.

How do I buy shares of ImmunoGen?

Shares of IMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ImmunoGen's stock price today?

One share of IMGN stock can currently be purchased for approximately $10.43.

How big of a company is ImmunoGen?

ImmunoGen has a market capitalization of $1.41 billion and generates $115.45 million in revenue each year. The biotechnology company earns $-96,010,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. ImmunoGen employs 293 workers across the globe.

How can I contact ImmunoGen?

ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-895-0600 or via email at [email protected]

MarketBeat Community Rating for ImmunoGen (IMGN)

Community Ranking:		2.5 out of 5 ( )
Outperform Votes:		299 (Vote Outperform)
Underperform Votes:		310 (Vote Underperform)
Total Votes:		609

MarketBeat's community ratings are surveys of what our community members think about ImmunoGen and other stocks. Vote "Outperform" if you believe IMGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMGN will underperform the S&P 500 over the long term. You may vote once every thirty days.

ImmunoGen (NASDAQ:IMGN) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

8 Wall Street analysts have issued ratings and price targets for ImmunoGen in the last 12 months. Their average twelve-month price target is $13.1667, suggesting that the stock has a possible upside of 26.24%. The high price target for IMGN is $20.00 and the low price target for IMGN is $5.00. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.75	2.75	2.56	2.50
Ratings Breakdown:	0 Sell Rating(s) 2 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 2 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 2 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$13.1667	$11.50	$9.4714	$8.05
Price Target Upside:	26.24% upside	11.00% upside	6.30% upside	64.96% upside

ImmunoGen (NASDAQ:IMGN) Consensus Price Target History

Price Target History for ImmunoGen (NASDAQ:IMGN)

ImmunoGen (NASDAQ:IMGN) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/17/2018	Cowen	Reiterated Rating	Hold		Medium
5/17/2018	HC Wainwright	Set Price Target	Buy	$18.00	Medium
4/27/2018	Canaccord Genuity	Reiterated Rating	Buy	$20.00	Low
4/8/2018	Cantor Fitzgerald	Set Price Target	Hold	$5.00	Low
3/26/2018	Leerink Swann	Reiterated Rating	Outperform		Medium
3/21/2018	Royal Bank of Canada	Boost Price Target	Outperform	$16.00	Low
10/12/2017	Jefferies Group	Reiterated Rating	Buy	$9.00	N/A
6/26/2017	William Blair	Reiterated Rating	Outperform		High
3/1/2017	Morgan Stanley	Lower Price Target	Underweight	$2.50 ➝ $1.30	N/A
8/5/2016	JPMorgan Chase & Co.	Set Price Target	Hold	$9.00 ➝ $5.00	N/A

(Data available from 5/26/2016 forward)

ImmunoGen (NASDAQ:IMGN) Earnings History and Estimates Chart

Earnings by Quarter for ImmunoGen (NASDAQ:IMGN)

ImmunoGen (NASDAQ:IMGN) Earnings Estimates

2018 EPS Consensus Estimate: ($1.08)
2019 EPS Consensus Estimate: ($1.26)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	2	($0.27)	($0.25)	($0.26)
Q2 2018	2	($0.28)	($0.27)	($0.28)
Q3 2018	2	($0.28)	($0.27)	($0.28)
Q4 2018	2	($0.28)	($0.26)	($0.27)
Q1 2019	1	($0.30)	($0.30)	($0.30)
Q2 2019	1	($0.30)	($0.30)	($0.30)
Q3 2019	1	($0.32)	($0.32)	($0.32)
Q4 2019	1	($0.34)	($0.34)	($0.34)

ImmunoGen (NASDAQ IMGN) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/4/2018	Q1 2018	($0.27)	($0.30)	$15.04 million	$19.80 million	View	N/A
2/9/2018	Q4 2017	($0.07)	($0.10)	$39.62 million	$39.40 million	View	Listen
11/3/2017	Q3 2017	($0.19)	($0.61)	$26.09 million	$8.50 million	View	N/A
7/28/2017	Q2 2017	($0.1660)	($0.10)	$30.59 million	$39.02 million	View	N/A
5/5/2017	3/31/2017	($0.36)	($0.20)	$16.16 million	$28.70 million	View	N/A
2/17/2017	Q2 2017	($0.39)	($0.39)	$16.28 million	$13.85 million	View	Listen
10/28/2016	Q117	($0.38)	($0.51)	$21.12 million	$7.66 million	View	Listen
8/4/2016	Q416	($0.39)	($0.51)	$17.11 million	$7.41 million	View	Listen
4/29/2016	Q316	($0.31)	($0.37)	$23.02 million	$19.71 million	View	Listen
1/29/2016	Q216	($0.36)	($0.38)	$19.54 million	$18.03 million	View	Listen
10/27/2015	Q116	($0.35)	($0.39)	$15.84 million	$14.90 million	View	Listen
7/31/2015	Q415	($0.34)	($0.35)	$15.42 million	$12.61 million	View	Listen
4/24/2015	Q315	($0.25)	($0.25)	$20.95 million	$11.40 million	View	Listen
1/30/2015	Q215	($0.06)	$0.16	$37.30 million	$48.30 million	View	Listen
10/24/2014	Q115	($0.14)	($0.26)	$21.80 million	$13.20 million	View	Listen
8/1/2014	Q414	($0.36)	($0.31)	$9.72 million	$5.74 million	View	N/A
4/25/2014	Q314	($0.27)	($0.44)	$13.28 million	$6.90 million	View	N/A
1/31/2014	Q214	($0.18)	($0.29)	$18.16 million	$30.10 million	View	Listen
10/25/2013	Q114	($0.23)	($0.13)	$12.10 million	$17.20 million	View	N/A
8/2/2013	Q4 2013	($0.30)	($0.26)	$3.44 million	$3.83 million	View	N/A
4/26/2013	Q3 2013	($0.15)	($0.02)	$11.94 million	$25.00 million	View	N/A
1/25/2013	Q2 2013	($0.25)	($0.29)	$6.02 million	$2.60 million	View	N/A
10/26/2012	Q113	($0.25)	($0.30)	$4.10 million	$4.10 million	View	N/A
8/3/2012		($0.30)	($0.29)			View	N/A
4/27/2012		($0.26)	($0.24)			View	N/A
1/27/2012		($0.22)	($0.17)			View	N/A
10/27/2011		($0.22)	($0.26)			View	N/A
8/3/2011		($0.24)	($0.23)			View	N/A
4/28/2011	Q1 2011	($0.23)	($0.22)			View	N/A
1/27/2011	Q4 2010	($0.22)	($0.21)			View	N/A
10/28/2010	Q3 2010	($0.23)	($0.19)			View	N/A
8/4/2010	Q2 2010	($0.24)	($0.21)			View	N/A
4/29/2010	Q1 2010	($0.23)	($0.21)			View	N/A
1/28/2010	Q4 2009	($0.21)	($0.23)			View	N/A
10/29/2009	Q3 2009	($0.20)	($0.22)			View	N/A
8/6/2009	Q2 2009	($0.17)	($0.21)			View	N/A
4/30/2009	Q1 2009	($0.10)	($0.09)			View	N/A
1/29/2009	Q4 2008	($0.15)	($0.14)			View	N/A
10/27/2008	Q3 2008	($0.21)	($0.19)			View	N/A
8/7/2008	Q2 2008	($0.25)	($0.27)			View	N/A
5/1/2008	Q1 2008	($0.21)	($0.30)			View	N/A
1/31/2008	Q4 2007	($0.11)	($0.15)			View	N/A

(Earnings results data provided by Zacks Investment Research)

ImmunoGen (NASDAQ:IMGN) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

ImmunoGen (NASDAQ IMGN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.51%
Institutional Ownership Percentage: 77.65%

Insider Trading History for ImmunoGen (NASDAQ:IMGN)

Institutional Ownership by Quarter for ImmunoGen (NASDAQ:IMGN)

ImmunoGen (NASDAQ IMGN) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/16/2018	Daniel M Junius	Director	Sell	25,000	$12.02	$300,500.00	209,987
3/15/2018	David Brannon Johnston	CFO	Sell	10,000	$11.53	$115,300.00	190,690
2/21/2018	David Brannon Johnston	CFO	Sell	21,060	$10.87	$228,922.20	180,690
2/21/2018	Mark J Enyedy	CEO	Sell	67,717	$10.87	$736,083.79	532,383
2/21/2018	Richard J Gregory	VP	Sell	34,486	$10.88	$375,207.68	239,094
2/20/2018	Daniel M Junius	Director	Sell	25,000	$11.68	$292,000.00	196,700
2/13/2018	Daniel M Junius	Director	Sell	46,667	$10.01	$467,136.67	243,367
1/8/2018	Richard J Gregory	VP	Sell	2,904	$6.64	$19,282.56	273,577
9/15/2017	Craig Barrows	VP	Sell	37,050	$6.81	$252,310.50	51,100
9/13/2017	Craig Barrows	VP	Sell	14,600	$6.95	$101,470.00	51,100
12/15/2016	Mark Alan Goldberg	Director	Buy	20,000	$1.80	$36,000.00	23,800
11/8/2016	Mark J Enyedy	CEO	Buy	25,000	$1.83	$45,750.00	100,100
11/2/2016	Craig Barrows	Insider	Buy	10,000	$1.71	$17,100.00	31,100
11/2/2016	Richard J Gregory	VP	Buy	16,600	$1.78	$29,548.00	39,231
2/1/2016	John Lambert	EVP	Sell	3,889	$8.22	$31,967.58	106,857
1/8/2016	Richard J Gregory	VP	Sell	2,369	$11.10	$26,295.90	22,631
1/4/2016	Daniel M. Junius	CEO	Sell	5,416	$13.17	$71,328.72	169,615
1/4/2016	John Lambert	EVP	Sell	3,889	$13.20	$51,334.80	106,857
12/1/2015	Daniel M. Junius	CEO	Sell	5,416	$13.11	$71,003.76	170,618
12/1/2015	John Lambert	EVP	Sell	3,889	$13.11	$50,984.79	106,857
11/27/2015	Charles Q Morris	VP	Sell	5,170	$14.00	$72,380.00	27,090
11/17/2015	Dean J Mitchell	Director	Buy	10,000	$12.51	$125,100.00	10,000
11/2/2015	Daniel M. Junius	CEO	Sell	5,497	$12.00	$65,964.00	159,812
11/2/2015	John Lambert	EVP	Sell	3,889	$11.73	$45,617.97	106,857
10/29/2015	Daniel M. Junius	CEO	Sell	5,335	$12.01	$64,073.35	154,115
10/1/2015	John Lambert	EVP	Sell	3,889	$9.55	$37,139.95	106,857
9/17/2015	David Brannon Johnston	CFO	Sell	5,000	$15.00	$75,000.00
9/1/2015	Daniel M. Junius	CEO	Sell	5,416	$13.15	$71,220.40	154,115
9/1/2015	John Lambert	EVP	Sell	3,889	$13.16	$51,179.24	106,857
7/1/2015	Daniel M Junius	CEO	Sell	5,416	$14.34	$77,665.44
7/1/2015	John Lambert	EVP	Sell	3,888	$14.34	$55,753.92
6/15/2015	Nicole Onetto	Director	Sell	3,211	$13.86	$44,504.46
6/1/2015	John Lambert	EVP	Sell	15,000	$11.78	$176,700.00
5/7/2015	Daniel M Junius	CEO	Sell	1,215	$8.02	$9,744.30
5/1/2015	John Lambert	EVP	Sell	10,000	$8.32	$83,200.00
11/28/2014	Charles Q Morris	VP	Sell	5,240	$10.40	$54,496.00
3/17/2014	Daniel Junius	CEO	Sell	15,000	$16.40	$246,000.00	80,636
2/26/2014	Charles Morris	VP	Sell	6,936	$17.35	$120,339.60	37,500
2/20/2014	Charles Morris	VP	Sell	13,672	$17.10	$233,791.20	37,500
2/18/2014	Daniel Junius	CEO	Sell	15,000	$16.26	$243,900.00	80,636
2/3/2014	John Lambert	EVP	Sell	4,375	$14.90	$65,187.50	106,857
1/22/2014	Charles Morris	VP	Sell	7,138	$17.00	$121,346.00	37,500
1/10/2014	Theresa Wingrove	VP	Sell	6,250	$15.04	$94,000.00
1/2/2014	John Lambert	EVP	Sell	4,375	$14.53	$63,568.75	106,857
12/10/2013	Daniel Junius	CEO	Sell	15,000	$15.11	$226,650.00	73,336
12/2/2013	John Lambert	EVP	Sell	4,375	$14.70	$64,312.50	106,857
11/26/2013	Charles Morris	VP	Sell	12,500	$13.75	$171,875.00	37,500
11/1/2013	John Lambert	EVP	Sell	4,375	$16.41	$71,793.75
9/10/2013	Gregory D Perry	CFO	Sell	18,337	$17.82	$326,765.34
9/3/2013	Daniel Junius	CEO	Sell	16,667	$16.43	$273,838.81	73,336
9/3/2013	John Lambert	EVP	Sell	4,375	$16.45	$71,968.75	106,857
8/1/2013	Daniel M Junius	CEO	Sell	16,667	$19.21	$320,173.07
8/1/2013	John Lambert	EVP	Sell	4,375	$19.21	$84,043.75
7/11/2013	James J O'leary	VP	Sell	35,000	$19.02	$665,700.00
7/3/2013	Daniel M Junius	CEO	Sell	16,667	$17.31	$288,505.77
7/1/2013	John Lambert	EVP	Sell	4,375	$16.80	$73,500.00
6/3/2013	John Lambert	EVP	Sell	11,250	$17.20	$193,500.00
5/24/2013	James J O'leary	VP	Sell	28,900	$18.11	$523,379.00
5/1/2013	John Lambert	EVP	Sell	11,250	$15.56	$175,050.00
4/11/2013	James J O'leary	VP	Sell	31,100	$17.37	$540,207.00
11/8/2012	Mark Alan Goldberg	Director	Buy	3,000	$11.27	$33,810.00

(Data available from 1/1/2013 forward)

ImmunoGen (NASDAQ IMGN) News Headlines

Source:

Date	Headline
	$14.15 Million in Sales Expected for ImmunoGen (IMGN) This Quarter www.americanbankingnews.com - May 26 at 3:28 AM
	Cowen Reaffirms "Hold" Rating for ImmunoGen (IMGN) www.americanbankingnews.com - May 17 at 4:33 PM
	ImmunoGen (IMGN) PT Set at $18.00 by HC Wainwright www.americanbankingnews.com - May 17 at 2:59 PM
	ImmunoGen's mirventuximab soravtansine shows positive effect in early-stage ovarian cancer study seekingalpha.com - May 17 at 2:31 PM
	BRIEF-Immunogen Announces Positive Findings From Forward 2 Study Of Mirvetuximab Soravtansine Combination ... www.reuters.com - May 17 at 10:02 AM
	Immunogen (IMGN) Reports Positive Findings from the FORWARD II Study of Mirvetuximab Soravtansine Combination ... www.streetinsider.com - May 17 at 10:02 AM
	ImmunoGen (IMGN) option implied volatility, says to present data from FORWARD II trial at ASCO www.streetinsider.com - May 17 at 10:02 AM
	Form 8-K IMMUNOGEN INC For: May 16 www.streetinsider.com - May 17 at 10:02 AM
	ImmunoGen Announces Positive Findings from the FORWARD II Study of Mirvetuximab Soravtansine Combination ... www.businesswire.com - May 17 at 10:02 AM
	ImmunoGen Announces Positive Findings from the FORWARD II Study of Mirvetuximab Soravtansine Combination Regimens with Avastin® and Carboplatin in Ovarian Cancer finance.yahoo.com - May 17 at 10:02 AM
	Analyzing ImmunoGen (IMGN) & AnaptysBio (ANAB) www.americanbankingnews.com - May 15 at 5:19 AM
	ImmunoGen (IMGN) Given Average Rating of "Buy" by Analysts www.americanbankingnews.com - May 15 at 1:40 AM
	Synaffix Further Strengthens Its Scientific Advisory Board with the Addition of John Lambert PhD, Former CSO of ... www.businesswire.com - May 14 at 11:12 AM
	ImmunoGen (IMGN) Lowered to Buy at BidaskClub www.americanbankingnews.com - May 10 at 12:36 AM
	ImmunoGen: An Extremely Promising ADC Therapeutic Innovator seekingalpha.com - May 9 at 4:10 PM
	Q2 2018 Earnings Estimate for ImmunoGen Issued By William Blair (IMGN) www.americanbankingnews.com - May 9 at 8:41 AM
	$15.00 Million in Sales Expected for ImmunoGen (IMGN) This Quarter www.americanbankingnews.com - May 9 at 4:44 AM
	ImmunoGen Presses Forward www.fool.com - May 8 at 8:49 PM
	ImmunoGen (IMGN) Q1 Loss Wider Than Expected, Revenues Beat finance.yahoo.com - May 7 at 10:12 AM
	ImmunoGen (IMGN) Expected to Announce Earnings of -$0.28 Per Share www.americanbankingnews.com - May 7 at 3:14 AM
	Edited Transcript of IMGN earnings conference call or presentation 4-May-18 12:00pm GMT finance.yahoo.com - May 5 at 10:06 AM
	ImmunoGen (IMGN) Releases Quarterly Earnings Results, Misses Estimates By $0.06 EPS www.americanbankingnews.com - May 4 at 8:33 PM
	ImmunoGen's (IMGN) CEO Mark Enyedy on Q1 2018 Results - Earnings Call Transcript seekingalpha.com - May 4 at 4:10 PM
	Form 8-K IMMUNOGEN INC For: May 04 www.streetinsider.com - May 4 at 9:45 AM
	ImmunoGen: 1Q Earnings Snapshot finance.yahoo.com - May 4 at 9:45 AM
	ImmunoGen (IMGN) Q1 Loss Wider, Revenues Beat finance.yahoo.com - May 4 at 9:45 AM
	ImmunoGen Announces Webcast of Presentation at Deutsche Bank's 43 www.businesswire.com - May 3 at 9:47 AM
	ImmunoGen Announces Webcast of Presentation at Deutsche Bank’s 43rd Annual Health Care Conference finance.yahoo.com - May 3 at 9:47 AM
	ImmunoGen (IMGN) Stock Rating Upgraded by BidaskClub www.americanbankingnews.com - May 2 at 1:10 PM
	What's in Store for ImmunoGen (IMGN) This Earnings Season? finance.yahoo.com - April 30 at 4:07 PM
	Form DEF 14A IMMUNOGEN INC For: Jun 20 www.streetinsider.com - April 30 at 10:47 AM
	What's in Store for ImmunoGen (IMGN) This Earnings Season? www.zacks.com - April 30 at 10:47 AM
	ImmunoGen (IMGN) Upgraded by ValuEngine to "Hold" www.americanbankingnews.com - April 27 at 10:20 PM
	ImmunoGen (IMGN) Given Buy Rating at Canaccord Genuity www.americanbankingnews.com - April 27 at 9:16 PM
	Why ImmunoGen, Inc. Stock Is on the Rise Today www.fool.com - April 27 at 1:42 PM
	BRIEF-Immunogen Completes Interim Analysis For Forward I Phase 3 Trial Of Mirvetuximab Soravtansine www.reuters.com - April 27 at 10:37 AM
	ImmunoGen Announces Successful Completion of Interim Analysis for FORWARD I Phase 3 Trial of Mirvetuximab ... www.businesswire.com - April 27 at 10:37 AM
	ImmunoGen Announces Successful Completion of Interim Analysis for FORWARD I Phase 3 Trial of Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer finance.yahoo.com - April 27 at 10:37 AM
	Here’s Why The Immunogen News Is Important For The Company finance.yahoo.com - April 27 at 10:37 AM
	ImmunoGen (IMGN) Scheduled to Post Earnings on Friday www.americanbankingnews.com - April 27 at 1:34 AM
	Form 3 IMMUNOGEN INC For: Apr 23 Filed by: McKee Blaine H. www.streetinsider.com - April 26 at 9:53 AM
	ImmunoGen (IMGN) Given a $18.00 Price Target at HC Wainwright www.americanbankingnews.com - April 26 at 8:00 AM
	ImmunoGen (IMGN) Short Interest Update www.americanbankingnews.com - April 26 at 2:22 AM
	ImmunoGen Appoints Blaine McKee as Executive Vice President and Chief Business Officer finance.yahoo.com - April 25 at 10:27 AM
	$15.29 Million in Sales Expected for ImmunoGen (IMGN) This Quarter www.americanbankingnews.com - April 22 at 4:56 AM
	ImmunoGen (IMGN) Given a $5.00 Price Target by Royal Bank of Canada Analysts www.americanbankingnews.com - April 20 at 2:25 PM
	ImmunoGen Announces Conference Call to Discuss Its First Quarter 2018 Operating Results finance.yahoo.com - April 20 at 10:03 AM
	ImmunoGen (IMGN) Receives Consensus Rating of "Hold" from Brokerages www.americanbankingnews.com - April 20 at 1:26 AM
	ImmunoGen (IMGN) Expected to Post Earnings of -$0.27 Per Share www.americanbankingnews.com - April 20 at 1:26 AM
	Stock Traders Buy High Volume of ImmunoGen Put Options (IMGN) www.americanbankingnews.com - April 19 at 8:32 AM

ImmunoGen (NASDAQ:IMGN) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

ImmunoGen (NASDAQ:IMGN) Income Statement, Balance Sheet and Cash Flow Statement

ImmunoGen (NASDAQ IMGN) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff